title: Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?
abstract: There is increasing evidence that certain kinase inhibitors are able to foster two strategies, i.e. inhibition of oncogenic activated molecular pathways and modulation of immunological processes. In this respect, the study of Tazzari et al. is of great interest because it shows both effects for the kinase inhibitor imatinib in dermatofibrosarcoma protuberans.
authors.affiliation: Department of Dermatology, University of Duisburg-Essen, Essen, Germany.
authors.forename: Selma
authors.initials: S
authors.lastname: Ugurel
authors.affiliation: Department of Dermatology, University of Duisburg-Essen, Essen, Germany; Translational Skin Cancer Research, German Cancer Consortium, West German Cancer Center, Essen, Germany. Electronic address: j.becker@dkfz.de.
authors.forename: Jürgen C
authors.initials: JC
authors.lastname: Becker
mesh_terms: D000970:Antineoplastic Agents; D001549:Benzamides; D018223:Dermatofibrosarcoma; D006801:Humans; D000068877:Imatinib Mesylate; D007167:Immunotherapy; D010879:Piperazines; D011743:Pyrimidines; D012878:Skin Neoplasms
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate